| NL129025C
              (en:Method)
            
            * | 1965-04-29 |  |  |  | 
        
          | US3542729A
              (en)
            
            * | 1968-03-19 | 1970-11-24 | Sankyo Co | Stabilization of synthetic polymers | 
        
          | BE790675A
              (fr)
            
            * | 1971-10-29 | 1973-04-27 | Science Union & Cie | Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane | 
        
          | US4244961A
              (en)
            
            * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents | 
        
          | US4255432A
              (en)
            
            * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof | 
        
          | ES8401072A1
              (es)
            
            * | 1982-11-23 | 1983-12-16 | Faes | Procedimiento de preparacion de un nuevo espirodecano. | 
        
          | HU204054B
              (en)
            
            * | 1989-08-10 | 1991-11-28 | Richter Gedeon Vegyeszet | Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same | 
        
          | YU150489A
              (sh)
            
            * | 1989-08-10 | 1992-12-21 | W.L. Gore & Co. Gmbh. | Uređaj za ispitivanje odevnih predmeta na nepromočivost | 
        
          | FR2666583B1
              (fr)
            
            * | 1990-09-06 | 1994-09-09 | Adir | Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant. | 
        
          | FR2734265B1
              (fr)
            
            * | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant | 
        
          | US6982251B2
              (en)
            
            * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents | 
        
          | ES2286233T3
              (es)
            
            * | 2001-01-26 | 2007-12-01 | Schering Corporation | Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares. | 
        
          | AR035739A1
              (es)
            
            * | 2001-01-26 | 2004-07-07 | Schering Corp | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares | 
        
          | ATE348649T1
              (de)
            
            * | 2001-01-26 | 2007-01-15 | Schering Corp | Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen | 
        
          | EP1671650A1
              (en)
            
            * | 2001-01-26 | 2006-06-21 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | 
        
          | AU2002237927B2
              (en)
            
            * | 2001-01-26 | 2005-04-21 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | 
        
          | PL205343B1
              (pl)
            
            * | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu | 
        
          | US7071181B2
              (en)
            
            * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors | 
        
          | AU2002308778A1
              (en)
            
            * | 2001-05-25 | 2002-12-09 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease | 
        
          | DE10130020A1
              (de)
            
            * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate | 
        
          | DE10146275A1
              (de) | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz | 
        
          | CA2460340C
              (en)
            
            * | 2001-09-21 | 2011-02-15 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | 
        
          | US20030119808A1
              (en)
            
            * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects | 
        
          | EP1427409B1
              (en)
            
            * | 2001-09-21 | 2008-10-15 | Schering Corporation | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | 
        
          | US7053080B2
              (en)
            
            * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | 
        
          | US7056906B2
              (en)
            
            * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | 
        
          | EP1545519B1
              (en) | 2002-08-19 | 2011-03-23 | Pfizer Inc. | Combination therapy for hyperproliferative diseases | 
        
          | CA2504878A1
              (en)
            
            * | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination | 
        
          | ES2311806T3
              (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. | 
        
          | US7192944B2
              (en)
            
            * | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | 
        
          | ES2318274T3
              (es) | 2003-03-07 | 2009-05-01 | Schering Corporation | Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia. | 
        
          | US7459442B2
              (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | 
        
          | US20050037063A1
              (en)
            
            * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies | 
        
          | JP2007510659A
              (ja)
            
            * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 | 
        
          | WO2005075484A2
              (en) | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators | 
        
          | US20060063803A1
              (en)
            
            * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | 
        
          | GT200600381A
              (es) | 2005-08-25 | 2007-03-28 |  | Compuestos organicos | 
        
          | US7741317B2
              (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators | 
        
          | US7888376B2
              (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors | 
        
          | US7919506B2
              (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives | 
        
          | US8383660B2
              (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives | 
        
          | EP2094643B1
              (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases | 
        
          | EP2142555A1
              (en)
            
            * | 2007-03-29 | 2010-01-13 | F. Hoffmann-Roche AG | Heterocyclic antiviral compounds | 
        
          | CA2688161C
              (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | 
        
          | US20100120694A1
              (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | 
        
          | US8969514B2
              (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 
        
          | ES2624828T3
              (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros | 
        
          | US9616097B2
              (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use | 
        
          | CN102766147B
              (zh)
            
            * | 2012-08-03 | 2015-07-15 | 无锡药兴医药科技有限公司 | 一种芬司匹利及其氢卤酸盐的制备方法 | 
        
          | WO2014151200A2
              (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders | 
        
          | EP2970384A1
              (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses | 
        
          | CN105143203A
              (zh) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 | 
        
          | AU2014274812B2
              (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 
        
          | GB201416346D0
              (en)
            
            * | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives | 
        
          | WO2016055901A1
              (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds | 
        
          | ES3007652T3
              (en) | 2019-01-18 | 2025-03-20 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof |